Prothrombin Complex Concentrates in Pediatric Cardiac Surgery: The Current State and the Future

Elena Ashikhmina, Sameh Said, Mark M. Smith, Vilmarie Rodriguez, William C. Oliver, Gregory A. Nuttall, Joseph A. Dearani, Hartzell V Schaff

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: After decades of practice of pediatric cardiac surgery, postoperative bleeding due to the immaturity of hemostasis, hemodilution, and hypothermia remains a concern. Recently, a new approach for adult coagulopathy after bypass has emerged. Prothrombin complex concentrates (PCCs), designed to treat bleeding in hemophilia patients, are safely and efficiently used off label for hemorrhage after bypass. However, optimal dosing, indications and contraindications, and laboratory tests to assess the efficacy of PCC use in children have not yet been established. This literature review outlines the challenges of bypass-related coagulopathy, the pharmacology, and the experience in use of PCCs, with a focus on their potential in pediatric cardiac surgery. Methods: After a thorough literature search of MEDLINE, Scopus, and Ovid databases using the term "prothrombin complex concentrate AND pediatric," 23 relevant articles were selected. Results: The data supporting successful use of PCCs in acquired coagulopathy after cardiac surgery in adults have been increasing. Although small volume, low immunogenicity, efficiency, and speed in correcting coagulopathy are attractive qualities of PCCs for pediatric practice, current evidence is only anecdotal. The main concerns are unknown dosing regimens, the inability to closely monitor the effects of PCCs in real time, and a possibility of thrombotic complications, which can be particularly devastating in young congenital cardiac patients whose lives frequently depend upon the patency of artificial shunts. Conclusions: Extensive, high-quality research is warranted to fill in the gaps of knowledge regarding using PCCs in pediatric cardiac practice.

Original languageEnglish (US)
JournalAnnals of Thoracic Surgery
DOIs
StateAccepted/In press - 2017

Fingerprint

Thoracic Surgery
Pediatrics
Hemorrhage
Hemodilution
prothrombin complex concentrates
Hemophilia A
Hemostasis
Hypothermia
MEDLINE
Databases
Pharmacology
Research

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Prothrombin Complex Concentrates in Pediatric Cardiac Surgery : The Current State and the Future. / Ashikhmina, Elena; Said, Sameh; Smith, Mark M.; Rodriguez, Vilmarie; Oliver, William C.; Nuttall, Gregory A.; Dearani, Joseph A.; Schaff, Hartzell V.

In: Annals of Thoracic Surgery, 2017.

Research output: Contribution to journalArticle

Ashikhmina, Elena ; Said, Sameh ; Smith, Mark M. ; Rodriguez, Vilmarie ; Oliver, William C. ; Nuttall, Gregory A. ; Dearani, Joseph A. ; Schaff, Hartzell V. / Prothrombin Complex Concentrates in Pediatric Cardiac Surgery : The Current State and the Future. In: Annals of Thoracic Surgery. 2017.
@article{a06e866931a243db9432e6f619258919,
title = "Prothrombin Complex Concentrates in Pediatric Cardiac Surgery: The Current State and the Future",
abstract = "Background: After decades of practice of pediatric cardiac surgery, postoperative bleeding due to the immaturity of hemostasis, hemodilution, and hypothermia remains a concern. Recently, a new approach for adult coagulopathy after bypass has emerged. Prothrombin complex concentrates (PCCs), designed to treat bleeding in hemophilia patients, are safely and efficiently used off label for hemorrhage after bypass. However, optimal dosing, indications and contraindications, and laboratory tests to assess the efficacy of PCC use in children have not yet been established. This literature review outlines the challenges of bypass-related coagulopathy, the pharmacology, and the experience in use of PCCs, with a focus on their potential in pediatric cardiac surgery. Methods: After a thorough literature search of MEDLINE, Scopus, and Ovid databases using the term {"}prothrombin complex concentrate AND pediatric,{"} 23 relevant articles were selected. Results: The data supporting successful use of PCCs in acquired coagulopathy after cardiac surgery in adults have been increasing. Although small volume, low immunogenicity, efficiency, and speed in correcting coagulopathy are attractive qualities of PCCs for pediatric practice, current evidence is only anecdotal. The main concerns are unknown dosing regimens, the inability to closely monitor the effects of PCCs in real time, and a possibility of thrombotic complications, which can be particularly devastating in young congenital cardiac patients whose lives frequently depend upon the patency of artificial shunts. Conclusions: Extensive, high-quality research is warranted to fill in the gaps of knowledge regarding using PCCs in pediatric cardiac practice.",
author = "Elena Ashikhmina and Sameh Said and Smith, {Mark M.} and Vilmarie Rodriguez and Oliver, {William C.} and Nuttall, {Gregory A.} and Dearani, {Joseph A.} and Schaff, {Hartzell V}",
year = "2017",
doi = "10.1016/j.athoracsur.2017.04.009",
language = "English (US)",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",

}

TY - JOUR

T1 - Prothrombin Complex Concentrates in Pediatric Cardiac Surgery

T2 - The Current State and the Future

AU - Ashikhmina, Elena

AU - Said, Sameh

AU - Smith, Mark M.

AU - Rodriguez, Vilmarie

AU - Oliver, William C.

AU - Nuttall, Gregory A.

AU - Dearani, Joseph A.

AU - Schaff, Hartzell V

PY - 2017

Y1 - 2017

N2 - Background: After decades of practice of pediatric cardiac surgery, postoperative bleeding due to the immaturity of hemostasis, hemodilution, and hypothermia remains a concern. Recently, a new approach for adult coagulopathy after bypass has emerged. Prothrombin complex concentrates (PCCs), designed to treat bleeding in hemophilia patients, are safely and efficiently used off label for hemorrhage after bypass. However, optimal dosing, indications and contraindications, and laboratory tests to assess the efficacy of PCC use in children have not yet been established. This literature review outlines the challenges of bypass-related coagulopathy, the pharmacology, and the experience in use of PCCs, with a focus on their potential in pediatric cardiac surgery. Methods: After a thorough literature search of MEDLINE, Scopus, and Ovid databases using the term "prothrombin complex concentrate AND pediatric," 23 relevant articles were selected. Results: The data supporting successful use of PCCs in acquired coagulopathy after cardiac surgery in adults have been increasing. Although small volume, low immunogenicity, efficiency, and speed in correcting coagulopathy are attractive qualities of PCCs for pediatric practice, current evidence is only anecdotal. The main concerns are unknown dosing regimens, the inability to closely monitor the effects of PCCs in real time, and a possibility of thrombotic complications, which can be particularly devastating in young congenital cardiac patients whose lives frequently depend upon the patency of artificial shunts. Conclusions: Extensive, high-quality research is warranted to fill in the gaps of knowledge regarding using PCCs in pediatric cardiac practice.

AB - Background: After decades of practice of pediatric cardiac surgery, postoperative bleeding due to the immaturity of hemostasis, hemodilution, and hypothermia remains a concern. Recently, a new approach for adult coagulopathy after bypass has emerged. Prothrombin complex concentrates (PCCs), designed to treat bleeding in hemophilia patients, are safely and efficiently used off label for hemorrhage after bypass. However, optimal dosing, indications and contraindications, and laboratory tests to assess the efficacy of PCC use in children have not yet been established. This literature review outlines the challenges of bypass-related coagulopathy, the pharmacology, and the experience in use of PCCs, with a focus on their potential in pediatric cardiac surgery. Methods: After a thorough literature search of MEDLINE, Scopus, and Ovid databases using the term "prothrombin complex concentrate AND pediatric," 23 relevant articles were selected. Results: The data supporting successful use of PCCs in acquired coagulopathy after cardiac surgery in adults have been increasing. Although small volume, low immunogenicity, efficiency, and speed in correcting coagulopathy are attractive qualities of PCCs for pediatric practice, current evidence is only anecdotal. The main concerns are unknown dosing regimens, the inability to closely monitor the effects of PCCs in real time, and a possibility of thrombotic complications, which can be particularly devastating in young congenital cardiac patients whose lives frequently depend upon the patency of artificial shunts. Conclusions: Extensive, high-quality research is warranted to fill in the gaps of knowledge regarding using PCCs in pediatric cardiac practice.

UR - http://www.scopus.com/inward/record.url?scp=85021149290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021149290&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2017.04.009

DO - 10.1016/j.athoracsur.2017.04.009

M3 - Article

C2 - 28648539

AN - SCOPUS:85021149290

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

ER -